Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 CONSENT OF ERNST & YOUNG LLP - SYNLOGIC, INC. | exhibit231eyconsent.htm |
| EX-31.2 - EXHIBIT 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER - SYNLOGIC, INC. | mirn_12312016x10kex312.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SYNLOGIC, INC. | mirn_12312016x10kex311.htm |
| EX-10.26(B) - EXHIBIT 10.26(B) O'NEILL EMPLOYMENT AGREEMENT - SYNLOGIC, INC. | exhibit1026boneillemployme.htm |
| EX-10..26(A) - EXHIBIT 10.26(A) O'NEILL OFFER LETTER - SYNLOGIC, INC. | exhibit1026aoneillofferlet.htm |
| EX-10.24(C) - EXHIBIT 10.24(C) IRVIN SEPARATION AGREEMENT - SYNLOGIC, INC. | exhibit1024cirvinseperatio.htm |
| 10-K - FORM 10-K - SYNLOGIC, INC. | mirn_12312016x10kdocument.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Mirna Therapeutics, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), Paul Lammers, Chief Executive Officer of the Company, and Alan Fuhrman, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
• | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
• | The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 14, 2017
/s/ Paul Lammers | |
Paul Lammers, M.D., M.Sc. | |
Chief Executive Officer | |
(Principal Executive Officer) | |
/s/ Alan Fuhrman | |
Alan Fuhrman | |
Chief Financial Officer | |
(Principal Financial & Accounting Officer) | |